Market Overview

Benzinga's Top Pre-Market Gainers

Share:
Related AEZS
Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research
Aeterna Zentaris Adds Hollings Cancer Center To Multi-National Phase 3 Trial In Endometrial Cancer
Aeterna Zentaris initiates capital raise (Seeking Alpha)
Related MRVL
Fast Money Halftime Report Final Trade From March 5
Big Short Interest Swings In Semiconductor Stocks
STX, WDC slump on BofA launches; MRVL, HTCH also off (Seeking Alpha)

Aeterna Zentaris (NASDAQ: AEZS) added 4.15% to $2.26 in the pre-market session. Aeterna Zentaris granted Special Protocol Assessment by the U.S. Food and Drug Administration for Phase 3 registration trial in endometrial cancer with AEZS-108.

Arena Pharmaceuticals (NASDAQ: ARNA) moved up 1.71% to $8.94 in the pre-market session. Arena Pharmaceuticals shares have jumped 370.05% over the past 52 weeks, while the S&P 500 index has gained 12.76% in the same period.

LSI (NYSE: LSI) soared 1.61% to $7.10 in the pre-market trading. Analysts at Wunderlich initiated coverage on shares of LSI with a “buy” rating.

Marvell Technology Group (NASDAQ: MRVL) surged 1.54% to $7.25 in the pre-market session. Analysts at Wunderlich initiated coverage on shares of Marvell with a “hold” rating.

Posted-In: Top Pre-Market GainersNews Pre-Market Outlook Markets Movers

 

Related Articles (AEZS + ARNA)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→